摘要
目的:探讨地西他滨联合CAG方案治疗难治性贫血伴原始细胞增多型骨髓增生异常综合征(MDSRAEB)及难治性急性髓系白血病(AML)的疗效及其安全性。方法:138例MDS-RAEB及难治性AML随机分为观察组(n=69)与对照组(n=69)。对照组采用CAG化疗方案,观察组在对照组基础上加用地西他滨治疗。两组疗程均为4周。比较两组MDS-RAEB患者和难治性AML患者的治疗疗效及药品不良反应发生情况。结果:观察组MDSRAEB患者治疗RR为70.00%,高于对照组的47.37%(P<0.05);观察组难治性AML治疗的RR为68.97%,高于对照组的41.94%(P<0.05)。治疗后,两组白细胞、血小板计数均较治疗前明显增加,血红蛋白则较前明显降低(P<0.05),且观察组白细胞、血小板计数高于对照组,血红蛋白水平低于对照组(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:地西他滨联合CAG方案治疗MDS-RAEB及难治性AML疗效显著,且未明显增加化疗毒副反应,安全性良好。
Objective： To explore the efficacy and safety on treatment of the myelodysplastic syndrome-RAEB and refractory acute myeloid leukemia（ AML） treated with the combination of the decitabine joint CAG scheme. Methods： 138 patients with MDS-RAEB / refractory AML were randomly divided into observation group（ n = 69） and control group（ n =69）. Control group was treated with CAG chemotherapy,the observation group was treated with combination of decitabine on the basis of the control group. The course of treatment was 4 weeks in two groups. Comparison of two groups of patients with MDS-RAEB or refractory AML about the treatment effect and adverse drug reactions. Results： The overall response rate（ RR） of treating MDS-RAEB（ 70. 00%） in the observation group was higher than that in the control group（ 47. 37%）（ P〈0. 05）; the RR of treating refractory AML in the observation group treatment（ 68. 97%） was higher than that in the control group（ 41. 94%）（ P〈0. 05）. After the treatment,the white blood cell count and platelet of two groups were increased significantly,the hemoglobin decreased significantly（ P〈0. 05）. The white blood cell count and platelet in the observation group were higher than that in the control group,and hemoglobin was lower than that of the control group（ P〈0. 05）. There was no significant difference in the adverse drug reaction between the two groups（ P〈0. 05）. Conclusion：The therapeutic effect of decitabine joint CAG scheme in the treatment of patients with myelodysplastic syndrome-RAEB and refractory AML was significant,and no significant increase in adverse drug reaction,safety was good.
出处
《药物流行病学杂志》
CAS
2016年第7期422-425,共4页
Chinese Journal of Pharmacoepidemiology
